These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4145866)

  • 41. [Butaperazine blood level determination by radioimmunoassay following oral application of Tyrylen drug forms].
    Hergert I; Hecht HF; Peinhardt G
    Pharmazie; 1986 Apr; 41(4):289. PubMed ID: 2873598
    [No Abstract]   [Full Text] [Related]  

  • 42. Prediction of changes in severity of the schizophrenic syndrome with discontinuation and administration of phenothiazines in chronic schizophrenic patients: language as a predictor and measure of change in schizophrenia.
    Gottschalk LA; Gleser GC; Cleghorn JM; Stone WN; Winget CN
    Compr Psychiatry; 1970 Mar; 11(2):123-40. PubMed ID: 5436410
    [No Abstract]   [Full Text] [Related]  

  • 43. Potential value of penfluridol and pipothiazine palmitate.
    Gallant DM
    Psychopharmacol Bull; 1975 Jan; 11(1):11-2. PubMed ID: 235769
    [No Abstract]   [Full Text] [Related]  

  • 44. Piperacetazine (Quide): a controlled evaluation of the elixir in chronic schizophrenic patients.
    Gallant DM; Bishop MP
    Curr Ther Res Clin Exp; 1970 Jun; 12(6):387-9. PubMed ID: 4987346
    [No Abstract]   [Full Text] [Related]  

  • 45. Long-acting phenothiazine preparations in the treatment of schizophrenia.
    Kernohan GA
    Br J Psychiatry; 1972 Jan; 120(554):126-7. PubMed ID: 5041515
    [No Abstract]   [Full Text] [Related]  

  • 46. Doxepin as adjuvant medication in the treatment of chronic schizophrenic patients: a comparative study.
    Sterlin C; Augustin E; Ban TA; Jarrold L
    Curr Ther Res Clin Exp; 1971 Jan; 13(1):50-2. PubMed ID: 4992566
    [No Abstract]   [Full Text] [Related]  

  • 47. Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients.
    Smith RC; Crayton J; Dekirmenjian H; Klass D; Davis JM
    Arch Gen Psychiatry; 1979 May; 36(5):579-84. PubMed ID: 35115
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High dose trifluoperazine therapy in chronic schizophrenia.
    Prien RF; Levine J; Cole JO
    Am J Psychiatry; 1969 Sep; 126(3):305-13. PubMed ID: 4895559
    [No Abstract]   [Full Text] [Related]  

  • 49. Carphenazine in the treatment of schizophrenic psychoses. Controlled clinical trial.
    Vinar O; Formánková M; Taussigová D; Růzicka S
    Act Nerv Super (Praha); 1967 Nov; 9(4):353-5. PubMed ID: 4889058
    [No Abstract]   [Full Text] [Related]  

  • 50. Molindone: a crossover evaluation of capsule and tablet formulations in severely ill schizophrenic patients.
    Gallant DM; Bishop MP; Steele CA; Bishop G; Guerrero-Figueroa R
    Curr Ther Res Clin Exp; 1973 Dec; 15(12):915-8. PubMed ID: 4203575
    [No Abstract]   [Full Text] [Related]  

  • 51. An uncontrolled clinical study with piperacetazine in the maintenance treatment of chronic schizophrenic patients.
    Amin MM; Brahm E; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1977 Jul; 13(3):10-1. PubMed ID: 18753
    [No Abstract]   [Full Text] [Related]  

  • 52. A fluorometric method for the measurement of butaperazine in human plasma.
    Manier DH; Sekerke J; Dingell JV; El-Yousef MK
    Clin Chim Acta; 1974 Dec; 57(3):225-30. PubMed ID: 4154816
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical and plasma level characteristics of intramuscular and oral loxapine.
    Simpson GM; Cooper TB; Lee JH; Young MA
    Psychopharmacology (Berl); 1978 Mar; 56(2):225-32. PubMed ID: 417377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The treatment of lobotomized schizophrenic patients with butaperazine.
    Holden JM; Itil TM; Keskiner A
    Curr Ther Res Clin Exp; 1969 Jul; 11(7):418-28. PubMed ID: 4390417
    [No Abstract]   [Full Text] [Related]  

  • 55. The use of LSD and ditran in the treatment of therapy resistant schizophrenics (symptom provocation approach).
    Itil TM; Keskiner S; Holden JM
    Dis Nerv Syst; 1969 Feb; 30(2):Suppl:93-103. PubMed ID: 4388281
    [No Abstract]   [Full Text] [Related]  

  • 56. Specific indications for different classes of phenothiazines.
    Hollister LE; Overall JE; Kimbell I; Pokorny A
    Arch Gen Psychiatry; 1974 Jan; 30(1):94-9. PubMed ID: 4148660
    [No Abstract]   [Full Text] [Related]  

  • 57. Phenothiazine effects in good premorbid schizophrenics divided into paranoid-nonparanoid status.
    Judd LL; Goldstein MJ; Rodnick EH; Jackson NL
    Arch Gen Psychiatry; 1973 Aug; 29(2):207-21. PubMed ID: 4582360
    [No Abstract]   [Full Text] [Related]  

  • 58. Plasma levels of mesoridazine and its metabolites and clinical response in acute schizophrenia after a single intramuscular drug dose.
    Gottschalk LA; Dinovo E; Bierner R
    Psychopharmacol Bull; 1975 Oct; 11(4):33-4. PubMed ID: 812135
    [No Abstract]   [Full Text] [Related]  

  • 59. Letter: Tricyclic antidepressants and phenothiazines.
    el-Yousef MK; Manier DH
    JAMA; 1974 Sep; 229(11):1419. PubMed ID: 4152942
    [No Abstract]   [Full Text] [Related]  

  • 60. A trial of fluphenazine enanthate in chronic schizophrenia.
    Millar J; Daniel GR
    Br J Psychiatry; 1967 Dec; 113(505):1431-2. PubMed ID: 4865296
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.